Eli Lilly unveiled the first batch of clinical data from its investigational next-generation FR-targeted ADC in platinum-sensitive ovarian cancer at the 2026 ESMO conference.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.